---
title: "Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301183970.md"
description: "Pfizer Inc. (PFE) shares rose 1.82% to $28.00 on Wednesday, outperforming the broader market as the S&P 500 and Dow Jones fell. This marks Pfizer's second consecutive day of gains, though it remains 4.14% below its 52-week high. While competitors like Johnson & Johnson, Eli Lilly, and Abbott Laboratories also saw increases, Pfizer's trading volume was lower than its 50-day average."
datetime: "2026-10-07T20:36:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301183970.md)
  - [en](https://longbridge.com/en/news/301183970.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301183970.md)
generator: "portal-rs"
---

# Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Pfizer Inc. (PFE) rose 1.82% to $28.00 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.22% to 7,801.77 and Dow Jones Industrial Average falling 0.66% to 51,179.87.

This was the stock's second consecutive day of gains.

Pfizer Inc. closed 4.14% below its 52-week high of $29.21, which the company achieved on September 3rd.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) rose 1.44% to $258.45, Eli Lilly & Co. (LLY) rose 2.70% to $1,188.72, and Abbott Laboratories (ABT) rose 0.58% to $98.73.

Trading volume (30.2 M) remained 5.7 million below its 50-day average volume of 35.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled October 7, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

10-07-26 1636ET

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer's TUKYSA Gets FDA Nod For Front-Line HER2+ Breast Cancer Maintenance](https://longbridge.com/en/news/301219305.md)
- [Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims](https://longbridge.com/en/news/300961499.md)
- [Pfizer Inc. (PFE) Reports Positive Phase 3 Results for LITFULO in Vitiligo](https://longbridge.com/en/news/300807263.md)
- [FACTBOX-Global healthcare companies invest billions to boost US presence](https://longbridge.com/en/news/301028209.md)
- [Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims](https://longbridge.com/en/news/300710264.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**